- |||||||||| Jynarque (tolvaptan) / Otsuka, Daliresp (roflumilast) / Allergan, AstraZeneca, Takeda
FDA event, Journal: Unveiling some FDA-approved drugs as inhibitors of the store-operated Ca(2+) entry pathway. (Pubmed Central) - Jul 1, 2019 Of these drugs, leflunomide and teriflunomide could suppress SOCE significantly at clinically-relevant doses and this provides for an additional mechanism towards the therapeutic utility of these drugs as immunosuppressants. The other three drugs namely lansoprazole, tolvaptan and roflumilast, were less potent in suppressing SOCE but were more selective and thus they may serve as novel scaffolds for future development of new, more efficacious SOCE inhibitors.
- |||||||||| leflunomide / generics
Journal: Leflunomide counter n aktn s cardiac hypertrophy. (Pubmed Central) - Jun 26, 2019 We further discuss the mechanisms underlying Akt activation and its effects on CH and review possible mechanisms of leflunomide effects. Despite some caveats, the availability of such a newly repurposed compound to treat CH can be a relevant advance.
- |||||||||| Orencia (abatacept) / BMS, Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J, Rituxan (rituximab) / Roche, Biogen
Clinical, Review, Journal: Safety of anti-rheumatic drugs in men trying to conceive: A systematic review and analysis of published evidence. (Pubmed Central) - Jun 5, 2019 There was no evidence found pertaining to the effects of male exposure to IVIG, tacrolimus, golimumab, anakinra or belimumab on fertility or pregnancy outcomes. These results provide further reassurance as to the safety of many DMARDs for men trying to conceive and will be useful when counselling men about risks of anti-rheumatic drugs to fertility and pregnancies, and following accidental conception.
- |||||||||| leflunomide / Generic mfg.
Enrollment open: PMRLEFRCT: Treatment With Leflunomide in Patients With Polymyalgia Rheumatica (clinicaltrials.gov) - Jun 3, 2019 P3, N=94, Recruiting, These results provide further reassurance as to the safety of many DMARDs for men trying to conceive and will be useful when counselling men about risks of anti-rheumatic drugs to fertility and pregnancies, and following accidental conception. Not yet recruiting --> Recruiting
- |||||||||| Journal: Management of Inflammatory Arthritis in pregnancy: a National Cross-Sectional Survey of Canadian rheumatologists. (Pubmed Central) - May 31, 2019
There was consensus with use of 4 biologics - adalimumab (81%), certolizumab (80%), etanercept (83%), and infliximab (76%) - in planned pregnancies but uncertainty on when they should be discontinued and their use in unplanned pregnancies. This national survey shows consensus among rheumatologists on the use of some csDMARDs and biologics/small molecules in IA patients planning pregnancy but varied knowledge on when to discontinue and what to do in unplanned pregnancies.
- |||||||||| TriptoSar (triptolide) / Pierre Fabre
Journal: Effects of Triptolide on the Autophagy in Synovial, Spleen and Thymus of Rats with Adjuvant Arthritis (Pubmed Central) - May 30, 2019 This national survey shows consensus among rheumatologists on the use of some csDMARDs and biologics/small molecules in IA patients planning pregnancy but varied knowledge on when to discontinue and what to do in unplanned pregnancies. TP regulates autophagy in synovial, thymus and spleen of AA rats, and improves theirjointinflammatory response.
- |||||||||| Vistide (cidofovir) / Gilead
Review, Journal: Antiviral treatment of BK virus viremia after kidney transplantation. (Pubmed Central) - May 30, 2019 A review of the published literature revealed that certain populations of patients with BKV viremia or BKVAN can benefit from cidofovir, leflunomide, and IVIG therapy, but these data were derived from case series or protocol-driven cohort studies. Providers should treat patients on an individual basis to maximize clinical effectiveness while limiting adverse reactions.
- |||||||||| Review, Journal: Recent advances in the management of Takayasu arteritis. (Pubmed Central) - May 29, 2019
Among bDMARDs, anti-tumor necrosis factor alpha agents and tocilizumab may be useful in patients refractory to cDMARDs with retardation of angiographic progression, based on evidence derived from mostly retrospective case series, whereas the role of rituximab and ustekinumab needs further elucidation...Emerging evidence suggests that patients with TA also have increased cardiovascular risk and this requires appropriate management. Large studies involving multiple centers are the need of the hour to appropriately evaluate utility of currently available immunosuppressive therapy in TA.
- |||||||||| methotrexate / generics, leflunomide / generics
Journal: Combination leflunomide and methotrexate impedes the recovery of liver fibrosis, partly through inhibition of myeloid cell admittance. (Pubmed Central) - May 29, 2019 Notably, the results of immunofluorescence staining of hepatic myeloid cells and detection of vascular growth factor A (VEGF‑A) in blood and liver suggested that the reduced degeneration of collagen in liver sinusoids was associated with decreased myeloid cell adhesion and the downregulation of VEGF‑A in the liver. The present results suggested that in certain cases, treatment with LEF+MTX may impede the recovery of hepatic fibrosis‑associated diseases in mice.
- |||||||||| Solodyn (minocycline) / Bausch Health, hydroxychloroquine / VG Lifesciences
Journal: Liquid Chromatography Based Methods for Analysis of Disease-Modifying Antirheumatic Drugs (DMARDs) in Biological Matrices. (Pubmed Central) - May 24, 2019 However, they have not been critically reviewed for pre-chromatographic sample preparation, chromatographic separation and sensitive detection. This review article can be handy for quantitation of DMARDs in diverse biological matrices as it provides comprehensive information on the reported liquid chromatographic methods for last three decades covering all the aspects required for preclinical and clinical studies.
- |||||||||| leflunomide / Generic mfg.
Enrollment open, Trial initiation date, Metastases: Leflunomide in Previously Treated Metastatic Triple Negative Cancers (clinicaltrials.gov) - Apr 19, 2019 P1/2, N=54, Recruiting, CP-25 inhibited p-ERK by reducing the membrane expression of GRK2 in FLS from AA rats. Not yet recruiting --> Recruiting | Initiation date: Oct 2018 --> Apr 2019
- |||||||||| tacrolimus / generics
FDA event, Review, Journal: An FDA-Approved Drug Screen for Compounds Influencing Craniofacial Skeletal Development and Craniosynostosis. (Pubmed Central) - Apr 13, 2019 As proof-of-concept, we also tested drug treatment of disease-relevant mammalian cells. While leflunomide treatment inhibited the viability of several human NCSC-derived neuroblastoma cell lines coincident with altered expression of genes involved in ribosome biogenesis and transcription, FK506 enhanced murine calvarial osteoblast differentiation and prevented fusion of the coronal suture in calvarial explants taken from Crouzon syndrome mice.
- |||||||||| teriflunomide / generics
Journal: Teriflunomide promotes oligodendroglial differentiation and myelination. (Pubmed Central) - Apr 7, 2019 Abatacept in combination with non-MTX csDMARDs is clinically effective and well tolerated in patients with moderate-to-severe RA, providing similar benefits to those seen with abatacept plus MTX. Our findings indicate a critical window of opportunity during which regenerative oligodendroglial activities including myelination of CNS axons can be stimulated by teriflunomide.
- |||||||||| teriflunomide / generics, leflunomide / generics
Journal: Antiviral activity of A771726, the active metabolite of leflunomide, against JunÃn virus. (Pubmed Central) - Apr 3, 2019 In conclusion, these results suggest that the antiviral target would be viral RNA synthesis through pyrimidine depletion, but any other effect of the compound on JUNV infection cannot be excluded. This study opens the possibility of the therapeutic application of a wide spectrum host-targeted compound alone or in combination with ribavirin to combat AHF as well as other human pathogenic arenaviruses.
- |||||||||| leflunomide / Generic mfg.
Trial completion: Leflunomide for Maintenance of Remission in IgG4 Related Disease (clinicaltrials.gov) - Mar 6, 2019 P4, N=68, Completed, This study opens the possibility of the therapeutic application of a wide spectrum host-targeted compound alone or in combination with ribavirin to combat AHF as well as other human pathogenic arenaviruses. Recruiting --> Completed
|